Cargando…

Kuhuang alleviates liver fibrosis by modulating gut microbiota-mediated hepatic IFN signaling and bile acid synthesis

Background: Liver fibrosis is a common outcome of the pathological progression of chronic liver disease; however, no specific and effective therapeutic agent has been approved for its treatment. We investigated the effects of Kuhuang on liver fibrosis and the underlying mechanisms of action. Materia...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Bo, Zhou, Cui, Gu, Tianyi, Shen, Zhenyang, Guo, Yuecheng, Dai, Weiming, Liu, Yang, Zhang, Jie, Lu, Lungen, Dong, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792617/
https://www.ncbi.nlm.nih.gov/pubmed/36582518
http://dx.doi.org/10.3389/fphar.2022.1080226
_version_ 1784859675807711232
author Shen, Bo
Zhou, Cui
Gu, Tianyi
Shen, Zhenyang
Guo, Yuecheng
Dai, Weiming
Liu, Yang
Zhang, Jie
Lu, Lungen
Dong, Hui
author_facet Shen, Bo
Zhou, Cui
Gu, Tianyi
Shen, Zhenyang
Guo, Yuecheng
Dai, Weiming
Liu, Yang
Zhang, Jie
Lu, Lungen
Dong, Hui
author_sort Shen, Bo
collection PubMed
description Background: Liver fibrosis is a common outcome of the pathological progression of chronic liver disease; however, no specific and effective therapeutic agent has been approved for its treatment. We investigated the effects of Kuhuang on liver fibrosis and the underlying mechanisms of action. Materials and methods: To induce hepatic fibrosis, either 3,5-diethoxycarbonyl-1,4-dihydro-collidine (DDC) diet was administered, or bile duct ligation (BDL) surgery was performed on C57BL/6 mice. Kuhuang was orally administered to mice for 7 days before and after bile duct ligation or 4 weeks with a DDC diet. Hematoxylin and eosin, Sirius red staining, and immunohistochemical analyses were performed to evaluate hepatic pathology. Hepatic interferon-β (IFN-β) levels were measured using an enzyme-linked immunosorbent assay. RNA sequencing was performed to examine the gene expression profiles of liver tissues. The mRNA expression of inflammatory, profibrotic, and bile acid (BA)-related genes was further validated by qRT-PCR. A targeted metabolomics assay revealed the alteration of the hepatic bile acid (BA) composition. The composition of the gut microbiota was determined via 16S rRNA sequencing. Results: Treatment with Kuhuang attenuated liver fibrosis and reduced the inflammatory response in bile duct ligation and DDC mouse models. In addition, the hepatic IFN signaling pathway was activated following Kuhuang treatment. Kuhuang treatment also significantly decreased hepatic levels of both primary and secondary BAs. In addition, Kuhuang treatment altered gut microbiota composition, with an increased abundance of interferon-inducing Akkermansia and decreased abundance of bile salt hydrolase-producing Lactobacillus, Clostridium, and Bifidobacterium. Furthermore, the abundance of Akkermansia was positively correlated with the hepatic mRNA expression levels of Ifna4, Ifnb, and Isg15, whereas that of Lactobacillus, Clostridium ( - ) sensu ( - ) stricto ( - ) 1, and Bifidobacterium was positively correlated with levels of bile acid synthesis-related genes. Conclusion: Our results suggest that Kuhuang plays a protective role during the progression of liver fibrosis, potentially by altering the composition of the gut microbiota, which consequently activates interferon signaling and inhibits bile acid synthesis in the liver.
format Online
Article
Text
id pubmed-9792617
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97926172022-12-28 Kuhuang alleviates liver fibrosis by modulating gut microbiota-mediated hepatic IFN signaling and bile acid synthesis Shen, Bo Zhou, Cui Gu, Tianyi Shen, Zhenyang Guo, Yuecheng Dai, Weiming Liu, Yang Zhang, Jie Lu, Lungen Dong, Hui Front Pharmacol Pharmacology Background: Liver fibrosis is a common outcome of the pathological progression of chronic liver disease; however, no specific and effective therapeutic agent has been approved for its treatment. We investigated the effects of Kuhuang on liver fibrosis and the underlying mechanisms of action. Materials and methods: To induce hepatic fibrosis, either 3,5-diethoxycarbonyl-1,4-dihydro-collidine (DDC) diet was administered, or bile duct ligation (BDL) surgery was performed on C57BL/6 mice. Kuhuang was orally administered to mice for 7 days before and after bile duct ligation or 4 weeks with a DDC diet. Hematoxylin and eosin, Sirius red staining, and immunohistochemical analyses were performed to evaluate hepatic pathology. Hepatic interferon-β (IFN-β) levels were measured using an enzyme-linked immunosorbent assay. RNA sequencing was performed to examine the gene expression profiles of liver tissues. The mRNA expression of inflammatory, profibrotic, and bile acid (BA)-related genes was further validated by qRT-PCR. A targeted metabolomics assay revealed the alteration of the hepatic bile acid (BA) composition. The composition of the gut microbiota was determined via 16S rRNA sequencing. Results: Treatment with Kuhuang attenuated liver fibrosis and reduced the inflammatory response in bile duct ligation and DDC mouse models. In addition, the hepatic IFN signaling pathway was activated following Kuhuang treatment. Kuhuang treatment also significantly decreased hepatic levels of both primary and secondary BAs. In addition, Kuhuang treatment altered gut microbiota composition, with an increased abundance of interferon-inducing Akkermansia and decreased abundance of bile salt hydrolase-producing Lactobacillus, Clostridium, and Bifidobacterium. Furthermore, the abundance of Akkermansia was positively correlated with the hepatic mRNA expression levels of Ifna4, Ifnb, and Isg15, whereas that of Lactobacillus, Clostridium ( - ) sensu ( - ) stricto ( - ) 1, and Bifidobacterium was positively correlated with levels of bile acid synthesis-related genes. Conclusion: Our results suggest that Kuhuang plays a protective role during the progression of liver fibrosis, potentially by altering the composition of the gut microbiota, which consequently activates interferon signaling and inhibits bile acid synthesis in the liver. Frontiers Media S.A. 2022-12-13 /pmc/articles/PMC9792617/ /pubmed/36582518 http://dx.doi.org/10.3389/fphar.2022.1080226 Text en Copyright © 2022 Shen, Zhou, Gu, Shen, Guo, Dai, Liu, Zhang, Lu and Dong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Shen, Bo
Zhou, Cui
Gu, Tianyi
Shen, Zhenyang
Guo, Yuecheng
Dai, Weiming
Liu, Yang
Zhang, Jie
Lu, Lungen
Dong, Hui
Kuhuang alleviates liver fibrosis by modulating gut microbiota-mediated hepatic IFN signaling and bile acid synthesis
title Kuhuang alleviates liver fibrosis by modulating gut microbiota-mediated hepatic IFN signaling and bile acid synthesis
title_full Kuhuang alleviates liver fibrosis by modulating gut microbiota-mediated hepatic IFN signaling and bile acid synthesis
title_fullStr Kuhuang alleviates liver fibrosis by modulating gut microbiota-mediated hepatic IFN signaling and bile acid synthesis
title_full_unstemmed Kuhuang alleviates liver fibrosis by modulating gut microbiota-mediated hepatic IFN signaling and bile acid synthesis
title_short Kuhuang alleviates liver fibrosis by modulating gut microbiota-mediated hepatic IFN signaling and bile acid synthesis
title_sort kuhuang alleviates liver fibrosis by modulating gut microbiota-mediated hepatic ifn signaling and bile acid synthesis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792617/
https://www.ncbi.nlm.nih.gov/pubmed/36582518
http://dx.doi.org/10.3389/fphar.2022.1080226
work_keys_str_mv AT shenbo kuhuangalleviatesliverfibrosisbymodulatinggutmicrobiotamediatedhepaticifnsignalingandbileacidsynthesis
AT zhoucui kuhuangalleviatesliverfibrosisbymodulatinggutmicrobiotamediatedhepaticifnsignalingandbileacidsynthesis
AT gutianyi kuhuangalleviatesliverfibrosisbymodulatinggutmicrobiotamediatedhepaticifnsignalingandbileacidsynthesis
AT shenzhenyang kuhuangalleviatesliverfibrosisbymodulatinggutmicrobiotamediatedhepaticifnsignalingandbileacidsynthesis
AT guoyuecheng kuhuangalleviatesliverfibrosisbymodulatinggutmicrobiotamediatedhepaticifnsignalingandbileacidsynthesis
AT daiweiming kuhuangalleviatesliverfibrosisbymodulatinggutmicrobiotamediatedhepaticifnsignalingandbileacidsynthesis
AT liuyang kuhuangalleviatesliverfibrosisbymodulatinggutmicrobiotamediatedhepaticifnsignalingandbileacidsynthesis
AT zhangjie kuhuangalleviatesliverfibrosisbymodulatinggutmicrobiotamediatedhepaticifnsignalingandbileacidsynthesis
AT lulungen kuhuangalleviatesliverfibrosisbymodulatinggutmicrobiotamediatedhepaticifnsignalingandbileacidsynthesis
AT donghui kuhuangalleviatesliverfibrosisbymodulatinggutmicrobiotamediatedhepaticifnsignalingandbileacidsynthesis